WASHINGTON, June 19,
2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR)
("Danaher" or the "Company"), a leading global life sciences and
diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim
Weidemanis as Executive Vice President, Diagnostics effective as of
July 1, 2024. Mr. Weidemanis will
support the transition over the next three months and will retire
from Danaher on September 30, 2024
after 13 years of service.
Ms. Sawyer Montgomery, currently
Vice President and Group Executive of Danaher's Clinical
Diagnostics businesses, will become an executive officer of Danaher
reporting to President and Chief Executive Officer, Rainer Blair.
Rainer Blair commented: "Julie's
exceptional leadership has been instrumental in driving growth and
improving performance at Beckman Coulter Diagnostics and, more
recently, across our Clinical Diagnostics businesses. During her
tenure Julie has shown tremendous commitment to supporting our
customers, building winning teams, driving innovation and leading
with the Danaher Business System. I look forward to seeing Julie
apply her skills and experiences to help ensure the ongoing success
of our entire Diagnostics franchise, as we work to improve outcomes
for patients with faster, more accurate diagnoses."
Ms. Sawyer Montgomery joined
Danaher in 2017. In her current role, she is responsible for
providing strategic leadership across Danaher's Diagnostics
businesses. Previously, she held positions of increasing
responsibility and was the President of Beckman Coulter
Diagnostics. Before joining Danaher, Ms. Sawyer Montgomery held leadership roles at
Hospira Infusion Systems, Boston Scientific and Boston Consulting
Group. She holds a Bachelor of Arts in Economics from Columbia University, a Master of Music from the
Eastman School of Music, and a Master
of Business Administration from Harvard
Business School.
Mr. Weidemanis joined Danaher in 2011. Among his many
accomplishments, he most recently led our Diagnostics businesses
and previously oversaw our Product Identification and Water Quality
platforms, which are now part of Veralto Corporation.
Mr. Blair added: "It has been a privilege to work alongside
Joakim for the past 13 years. His contributions have been pivotal
in evolving strategy, furthering growth, innovation, operational
excellence and developing leaders across our businesses. On behalf
of our Board of Directors, associates and shareholders, I want to
thank Joakim for helping to make Danaher a better, stronger
company."
ABOUT DANAHER
Danaher is a leading global life
sciences and diagnostics innovator, committed to accelerating the
power of science and technology to improve human health. Our
businesses partner closely with customers to solve many of the most
important health challenges impacting patients around the world.
Danaher's advanced science and technology - and proven ability to
innovate - help enable faster, more accurate diagnoses and help
reduce the time and cost needed to sustainably discover, develop
and deliver life-changing therapies. Focused on scientific
excellence, innovation and continuous improvement, our
approximately 63,000 associates worldwide help ensure that Danaher
is improving quality of life for billions of people today, while
setting the foundation for a healthier, more sustainable tomorrow.
Explore more at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release
that are not strictly historical, including the statement regarding
the prospects for our Diagnostics businesses and any other
statements regarding events or developments that we believe or
anticipate will or may occur in the future are "forward-looking"
statements within the meaning of the federal securities laws. There
are a number of important factors that could cause actual results,
developments and business decisions to differ materially from those
suggested or indicated by such forward-looking statements and you
should not place undue reliance on any such forward-looking
statements. These factors include, among other things:
unanticipated, further declines in demand for our COVID-19 related
products, the impact of global health crises, the impact of our
debt obligations on our operations and liquidity, deterioration of
or instability in the global economy, the markets we serve and the
financial markets, uncertainties with respect to the development,
deployment, and use of artificial intelligence in our business and
products, uncertainties relating to national laws or policies,
including laws or policies to protect or promote domestic interests
and/or address foreign competition, contractions or growth rates
and cyclicality of markets we serve, competition, our ability to
develop and successfully market new products and technologies and
expand into new markets, the potential for improper conduct by our
employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to
off-label marketing and other regulations relating to medical
devices and the health care industry), the results of our clinical
trials and perceptions thereof, our ability to effectively address
cost reductions and other changes in the health care industry, our
ability to successfully identify and consummate appropriate
acquisitions and strategic investments, our ability to integrate
the businesses we acquire and achieve the anticipated growth,
synergies and other benefits of such acquisitions, contingent
liabilities and other risks relating to acquisitions, investments,
strategic relationships and divestitures (including tax-related and
other contingent liabilities relating to past and future IPOs,
split-offs or spin-offs), security breaches or other disruptions of
our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to
grow, risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the
United States government with respect to our production
capacity in times of national emergency or with respect to
intellectual property/production capacity developed using
government funding, risks relating to product, service or software
defects, product liability and recalls, risks relating to our
manufacturing operations and fluctuations in the cost and
availability of the supplies we use (including commodities) and
labor we need for our operations, our relationships with and the
performance of our channel partners, uncertainties relating to
collaboration arrangements with third-parties, the impact of
deregulation on demand for our products and services, the impact of
climate change, legal or regulatory measures to address climate
change and our ability to address stakeholder expectations relating
to climate change, labor matters and our ability to recruit, retain
and motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal,
compliance, social and business factors (including the impact of
military conflicts), disruptions relating to man-made and natural
disasters, inflation and the impact of our By-law exclusive forum
provisions. Additional information regarding the factors that
may cause actual results to differ materially from these
forward-looking statements is available in our SEC filings,
including our 2023 Annual Report on Form 10-K and Quarterly Report
on Form 10-Q for the first quarter of 2024. These
forward-looking statements speak only as of the date of this
release and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise.
View original
content:https://www.prnewswire.com/news-releases/danaher-appoints-julie-sawyer-montgomery-to-executive-vice-president-for-diagnostics-302176255.html
SOURCE Danaher Corporation